Adherence in bronchiectasis (BQ) and concordance between multidimensional scales in a cohort of patients colonized by Pseudomonas aeruginosa (PsA)

Objectives: Comparison of adherence to nebulized sodium colistimethate (Promixin) and agreement between the multidimensional FACED, E-FACED and BSI scales in a cohort of patients with non-cystic fibrosis BQ and chronic bronchial infection (CBI) by PsA. Patients and Methods: A multicenter, observational, longitudinal prospective study of a cohort of adults with non-CF BQ, all with PsA CBI and treated with Promixin. FACED, EFACED and BSI scales in the previous year, their modification after a year of treatment with the nebulized therapy and the concordance between them are collected. Results: 99 patients were started average age 63±14.7 years. In the year prior to treatment FEV1 was 55±19%, exacerbations 3.8±2.6 and 0.5±0.7 hospital admissions/year. At the end FEV1 was 59±22%, exacerbations/year 1.4±1.2 and hospital admissions/year 0.26±0.6. In the pretreatment assessment there is a low concordance between the EFACED and BSI scales (R=0,248; p Conclusions: In our cohort there is good adherence to nebulized treatment with Promixin® and good nebulizer management, regardless of the severity of BQ. These results have their clinical impact in terms of functional improvement, reduction of exacerbations and changes in the level of severity prior to treatment. Given the concordance between the prognostic scales, both could be applicable to assess sensitivity to change in a therapeutic intervention with nebulized antibiotics.